Modeled first AML driver preceded age 20 in two-thirds of 47 women; childhood blood was not sampled

A University of Cambridge and UCL team, writing in Nature and reported by Medical Xpress, reconstructed pre-diagnosis evolution of acute myeloid leukemia using annual blood samples from the UK Collaborative Trial of Ovarian Cancer Screening. Among 47 women later diagnosed at a mean age of 72, modeling placed the first cancer-driving mutation before age 20 in about two-thirds, more than 50 years earlier. Matched samples from 46 women who remained free of blood cancer provided the contrast. The news account does not state funding.

Investigators used ultrasensitive DNA sequencing plus mathematical models to estimate when mutations arose and how fast clones expanded. The stored samples reach back about 15 years, not to childhood, so early timings are extrapolations. Clones carrying one driver reportedly doubled over years; each added driver raised growth roughly two- to threefold, and four-driver clones doubled in weeks. In at least one-third of cases a clone swept the blood years before diagnosis. No sweeps were reported in controls. UK Biobank data were said to show greatly increased risk, but the release gives no absolute risk.

This sits downstream of clonal hematopoiesis research, not as a first sighting of pre-leukemic mutations. Jaiswal and colleagues in the New England Journal of Medicine in 2014 linked age-related blood mutations to later hematologic cancer at low absolute rates. Abelson and colleagues in Nature in 2018 showed mutation patterns can stratify near-term AML risk, still with most high-risk people not developing disease over short follow-up. Watson, Blundell and colleagues in Science in 2020 described predictable clone growth. What the fossil-record framing blurs is that childhood acquisition here is modeled, the serial cohort is women only, and n equals 47.

Evidence quality: this is a retrospective nested comparison with genomic reconstruction and an external association analysis, not a randomized trial and not proof that slowing a clone prevents AML. It can show that, in these women, late expansions were orderly and sweeps were enriched before diagnosis. It cannot establish childhood timing by direct sampling, male generalizability, or a clinically validated risk tool. Base rate matters: about 2,700 UK AML diagnoses a year means even a large relative increase can leave absolute risk modest. Next needed is a pre-registered, sex-inclusive prospective test of sweep calls against absolute incidence, with funding disclosed.